Mark Dudley

Company: Instil Bio

Job title: Chief Scientific Officer

Seminars:

Developing a Novel Costimulatory Antigen Receptor With Dual CD28/ CD40 Signaling Domains to Improve Adoptive Cell Therapies 11:30 am

• Utilizing a novel platform to overcome poor endogenous costimulation and leverage the diverse TCR repertoire of TILs while amplifying antitumor activity • Improving primary human ovarian TIL function • Optimizing TIL therapies to improve scalability, logistics and accessibilityRead more

day: Day One

Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL 8:30 am

TIL therapies have come a long way since the pioneering work of Dr Rosenberg in the late 80s and the opportunity TIL provides to improve and expand on current immunotherapeutic treatments holds a great deal of promise. Key themes and questions to be explored include: •Discussing the key lessons learned from past developments to apply…Read more

day: Day One